Publications by authors named "Paulo Cesar Grippa"
Sarcopenia is a multifactorial condition related to the loss of muscle mass and strength due to aging, eating habits, physical inactivity, or even caused by another disease. Affected individuals have a higher risk of falls and may be associated with heart disease, respiratory diseases, cognitive impairment, and consequently an increased risk of hospitalization, in addition to causing an economic impact due to the high cost of care during the stay in hospitals. The standardization of appropriate treatment for patients with sarcopenia that could help reduce pathology-related morbidity is necessary.
View Article and Find Full Text PDFThe Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review.
Rodrigo Zamignan Carpi Sandra M Barbalho Katia Portero Sloan Lucas Fornari Laurindo Heron Fernando Gonzaga Paulo Cesar Grippa
Int J Mol Sci
August 2022
Article Synopsis
- Changes in gut microbiota due to environmental and genetic factors can disrupt intestinal balance, leading to metabolic and immune issues that heighten the risk of non-alcoholic fatty liver disease (NAFLD).
- Probiotics, prebiotics, and synbiotics are being explored as potential strategies to regulate gut microbiota and improve health in liver disease patients, with research indicating they can positively affect inflammation, glycemia, and liver injury indicators.
- Although these microbiota-modulating treatments aren't a cure, they can serve as useful adjunct therapies for NAFLD by enhancing gut health and immune response, thereby potentially mitigating liver damage.